Visfatin levels are low in subjects with type 2 diabetes compared to age-matched controls


Background: Visceral adiposity correlates strongly with insulin resistance and components of metabolic syndrome. Visfatin is preferentially produced by human visceral adipose tissue. Objective: The objective of this study was to evaluate the relationship between circulating levels of visfatin and other adipocytokines in patients with type 2 diabetes (DM) compared to the age-matched control subjects without DM. Methods: Anthropometric parameters, lipid profiles, high-sensitivity CRP (hs-CRP), insulin resistance [HOMA-IR], and levels of visfatin, TNF-α, and resistin were evaluated in 55 subjects with diabetes and 56 age matched control subjects without diabetes. Results: The visfatin levels were significantly lower in subjects with diabetes (p < 0.0001). Visfatin levels correlated strongly with resistin and CRP. We noted negative correlation of visfatin levels with BMI, triglycerides and glucose. Conclusion: These data suggest that visfatin may be a marker of subclinical inflammatory state.

Share and Cite:

Yaturu, S. , Davis, J. , Franklin, L. , Shi, R. , Venkatesh, P. and K. Jain, S. (2012) Visfatin levels are low in subjects with type 2 diabetes compared to age-matched controls. Journal of Diabetes Mellitus, 2, 373-377. doi: 10.4236/jdm.2012.24058.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Samal, B., et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molecular and Cellular Biology, 14, 1431-1437.
[2] Luk, T., Malam, Z. and Marshall, J.C. (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity. Journal of Leukocyte Biology, 83, 804-816. doi:10.1189/jlb.0807581
[3] Fukuhara, A., et al. (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science, 307, 426-430. doi:10.1126/science.1097243
[4] Li, L., et al. (2006) Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Experimental and Clinical Endocrinology & Diabetes, 114, 544-548. doi:10.1055/s-2006-948309
[5] Esteghamati, A., et al. (2011) Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Research and Clinical Practice, 91, 154-158. doi:10.1016/j.diabres.2010.11.003
[6] Filippatos, T.D., et al. (2007) Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. Journal of Endocrinological Investigation, 30, 323-326.
[7] Chen, M.P., et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 91, 295-299. doi:10.1210/jc.2005-1475
[8] McGee, K.C., et al. (2011) Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkappaB and JNK in human abdominal subcutaneous adipocytes. PLoS One, 6, e20287. doi:10.1371/journal.pone.0020287
[9] Kadoglou, N.P., et al. (2010) Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism, 59, 373-379. doi:10.1016/j.metabol.2009.08.005
[10] Straburzynska-Lupa, A., et al. (2010) Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clinical and Experimental Rheumatology, 28, 19-24.
[11] Stofkova, A., (2010) Resistin and visfatin: Regulators of insulin sensitivity, inflammation and immunity. Endocrine Regulations, 44, 25-36. doi:10.4149/endo_2010_01_25
[12] Samara, A., et al. (2008) Visfatin, low-grade inflammation and body mass index (BMI). Clinical Endocrinology (Oxford), 69, 568-574. doi:10.1111/j.1365-2265.2008.03205.x
[13] Esteghamati, A., et al. (2012) The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis. Journal of Cardiovascular Translational Research, 5, 541-546. doi:10.1007/s12265-012-9373-8
[14] Liu, S.W., (2009) et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clinical Endocrinology (Oxford), 71, 202-207. doi:10.1111/j.1365-2265.2008.03453.x
[15] Zhong, M., et al. (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clinical Endocrinology (Oxford), 69, 878-884. doi:10.1111/j.1365-2265.2008.03248.x
[16] Chang, Y.H., et al. (2011) Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Diabetes/Metabolism Research and Reviews, 27, 515-527. doi:10.1002/dmrr.1201
[17] Takebayashi, K., et al. (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism, 56, 451-458. doi:10.1016/j.metabol.2006.12.001
[18] Hammarstedt, A., et al. (2006) Visfatin is an adipokine, but it is not regulated by thiazolidinediones. The Journal of Clinical Endocrinology & Metabolism, 91, 1181-1184. doi:10.1210/jc.2005-1395
[19] Oki, K., et al. (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical Endocrinology (Oxford), 67, 796-800. doi:10.1111/j.1365-2265.2007.02966.x
[20] Kadoglou, N.P., et al. (2010) Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes, 118, 75-80. doi:10.1055/s-0029-1237360
[21] Peiro, C., et al. (2010) Visfatin/PBEF/Nampt: A new cardiovascular target? Frontiers in Cardiovascular and Smooth Muscle Pharmacology, 1, 135. doi:10.3389/fphar.2010.00135

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.